Helping to change lives with advancements in genetic medicine
At Asklepios BioPharmaceutical (AskBio), we are making history with every clinical advancement and aspire to turn hope into treatments by unraveling new possibilities for genetic medicine. We became a wholly owned, independently operated subsidiary of Bayer AG in late 2020 as a cornerstone of its newly formed Cell & Gene Therapy Platform.
AskBio is headquartered in Research Triangle Park, North Carolina, a thriving biotechnology hub with nearly 600 life science companies. Research and development facilities are located in Philadelphia, Pennsylvania; Upper Arlington, Ohio; and globally in Edinburgh, Scotland; Heidelberg, Germany; and Paris, France; and a gene therapy manufacturing facility located in San Sebastian, Spain.
Started in 2001, we are on a never-ending quest to advance genetic technology and develop gene therapy with the potential to significantly impact patients. We are singularly focused on a goal to successfully treat genetic disease. It is an audacious goal that will not be accomplished by us alone, but it is one to which we have already made significant contributions.
Almost 40 years ago, AskBio’s scientific co-founder, Jude Samulski, PhD, was the first to demonstrate that adeno-associated virus (AAV) could be cloned for therapeutic purposes. His groundbreaking research propelled one of the most exciting fields in medical research today. His work inspires our gene therapy platform that is intent on bringing new gene therapies to market with a lower cost.
AskBio today
Our clinical pipeline covers a broad range of central nervous system, neuromuscular, metabolic and cardiovascular disorders. We also have a number of research initiatives taking place to expand our pipeline that we believe will impact the future of other important therapeutics.
Our technology and AAV therapeutic assets have been acquired or licensed by leading pharmaceutical companies such as Bayer, Pfizer, Takeda and Novartis. This helps to validate leadership in gene therapy development and is even more significant considering that two of the first FDA-approved gene therapies are based on the research of our founders and AskBio’s current technology.
We welcome hearing from you if you would like more information about AskBio.
Meeting the challenges of genetic medicine
Our scientific and clinical teams are working to solve some of the most complex problems facing biotechnology and gene therapy.
- Extensive global research collaborations
- Integrated gene therapy platform includes a high-yield cell line, an expansive capsid library, and synthetic promoters and DNA
- New delivery methods to accelerate and lower the cost of producing therapeutics
- Over 350,000 square feet of lab, research and scaled in-house AAV manufacturing
- Foundational scientific expertise resulting in a portfolio of 800+ patents and patent applications for gene therapy development, clinical processes and manufacturing
- Rapidly expanding pipeline of investigational treatments
Jude Samulski story
Jude Samulski was a graduate student at the University of Florida when he discovered the possibilities of the AAV virus.
Leadership team
The AskBio leadership team has some of the best minds in science, clinical development and commercialization.
Board of directors
AskBio’s board of directors plays an integral role in our success as they help guide our world-class, leading gene therapy company.
Join our team and live an AskLife
Our team is passionately driven to change lives. As a rapidly growing company, we’re looking for like-minded people who value a patient-focused company where the next discovery is only the beginning.
